Notes: March 18, 2019 -- PDS Biotechnology Corporation, a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced the closing of its merger with Edge Therapeutics, Inc., following the approval of Edge stockholders on March 14, 2019. Following the merger, Edge will operate as PDS Biotechnology Corporation and the stock will trade on the Nasdaq Capital Market beginning on March 18, 2019 under the ticker symbol "PDSB." In connection with the closing of the merger, Edge effected a 20-1 reverse split of its common stock. Shares of the combined company's common stock will begin trading on a split-adjusted basis under the new ticker symbol on the Nasdaq Capital Market on March 18, 2019. Immediately following the completion of the merger and the reverse stock split, the total number of issued and outstanding shares of the combined company’s common stock will be 5,348,174